Analysis index

1 ml citrate plasma, frozen

70 % – 120 %

Children: Please refer to findings report

• Evaluation of increased PTT
• Suspicion of hemophilia B (prevalence 1:70.000)

Interpretation of activity:

70 % – 50 % no increased risk of bleeding

50 % – 25 % subhemophilia B, in most cases sufficient hemostasis

5 % – 25 % mild hemophilia B, depending on the type of defect, there may be an increased risk of bleeding

< 5 % moderate to severe hemophilia B, marked risk of bleeding

In very rare cases, patients may acquire hemophilia B (pregnant women or patients > 60 years of age).

When taking DOAKs (Dabigatran, Rivaroxaban, Apixaban or Edoxaban), an evaluation of the factor activity should be sought before the next dose.

Factor IX is vitamin-K dependent.